Parker Institute for Cancer Immunotherapy shared a post on LinkedIn:
“We’re thrilled to share that Alice Lin Pomponio is joining PICI as SVP, Corporate Development and Strategic Partnerships.
As an impact investor and innovation leader with experience across life sciences, venture investing, and public-private partnerships, Alice will help guide our strategy to advance transformative cancer research and accelerate new approaches to prevention, detection, and treatment.
Please join us in welcoming Alice to PICI!”
Karen Knudsen, Chief Executive Officer and Executive Director at Parker Institute for Cancer Immunotherapy, shared Parker Institute for Cancer Immunotherapy’s post, adding:
“What a tremendous joy to work again with Alice Lin Pomponio! Looking forward to April 1 when she joins us at Parker Institute for Cancer Immunotherapy to lead Corporate Development + Strategic Partnerships. Alice was the mastermind behind BrightEdge – American Cancer Society and remains a game changer…for the science and most importantly for cancer patients.
The ‘bench to bedside to marketplace’ PICI model is unique and one that Alice is uniquely poised to accelerate– uniting the world’s top cancer researchers though our Parker Institutes to accelerate discoveries, then to drive those breakthroughs thru our innovation + venture arms to get science to patients, faster. This Only works with leaders who can forge the right partnerships and fuel that pipeline. Alice is 100% that leader.
This is great news for everyone. Welcome to the Parker family, Alice!”
Other articles featuring Karen Knudsen and Parker Institute for Cancer Immunotherapy on OncoDaily.